The Drug Discovery World Podcast DDW Highlights: 28 July 2025
Jul 28, 2025
Dive into groundbreaking advancements in drug manufacturing, with major investments from AstraZeneca and Biogen leading the charge. Learn about the challenges faced by Ultragenyx Pharmaceutical as the FDA rejects their gene therapy over manufacturing issues. Discover how new UK regulations are reshaping personalized medicine, making treatments like CAR-T more accessible. This overview highlights the exciting shifts in the industry towards innovative manufacturing and tailored patient care.
AI Snips
Chapters
Transcript
Episode notes
Automation to Scale Cell Therapy
- Cell therapy development outruns manufacturing capacity, limiting patient access globally.
- Automated, robotic, and AI-driven manufacturing can revolutionize production scale and reach.
AstraZeneca’s Major US Investment
- AstraZeneca plans a $50 billion US investment by 2030 focusing on manufacturing.
- New Virginia facility will produce small molecules, peptides, and oligonucleotides for metabolic drugs.
Biogen Expands Automated Manufacturing
- Biogen will invest $2 billion more in North Carolina for advanced automation.
- Expansion includes antisense oligonucleotide capabilities and multi-platform fill-finish infrastructure.